Tokyo (JCN) Dec 21, 2005 - Eisai has announced that its US subsidiary Eisai Medical Research resubmitted a supplemental new drug application (sNDA) for Aricept, the company’s proprietary agent for treating severe Alzheimer’s disease, to the US Food and Drug Administration (FDA) as of December 16.